0001683168-23-007108.txt : 20231012
0001683168-23-007108.hdr.sgml : 20231012
20231012180010
ACCESSION NUMBER: 0001683168-23-007108
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230914
FILED AS OF DATE: 20231012
DATE AS OF CHANGE: 20231012
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cockroft Bettina M.
CENTRAL INDEX KEY: 0001900452
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39126
FILM NUMBER: 231323507
MAIL ADDRESS:
STREET 1: C/O ANNEXON, INC.
STREET 2: 180 KIMBALL WAY, SUITE 200
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001729427
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 822318545
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2100 WEST LOOP SOUTH
STREET 2: SUITE 900
CITY: HOUSTON
STATE: TX
ZIP: 77027
BUSINESS PHONE: 1-800-946-9185
MAIL ADDRESS:
STREET 1: 2100 WEST LOOP SOUTH
STREET 2: SUITE 900
CITY: HOUSTON
STATE: TX
ZIP: 77027
4/A
1
ownership.xml
X0508
4/A
2023-09-14
2023-09-25
0
0001729427
CNS Pharmaceuticals, Inc.
CNSP
0001900452
Cockroft Bettina M.
C/O CNS PHARMACEUTICALS, INC
100 WEST LOOP SOUTH, SUITE 900
HOUSTON
TX
77027
1
0
0
0
0
Option to purchase common stock
2.27
2023-09-14
4
A
0
6500
A
2033-09-14
Common Stock
6500
8599
D
Option to purchase common stock
1.09
2023-09-21
4
A
0
9475
A
2033-09-22
Common Stock
9475
18074
D
The stock options set forth in this table vest in 36 equal monthly installments. The stock option was approved by the compensation committee of the company's board of directors on August 4, 2023, subject to shareholder approval of the 2020 Stock Plan under which the option was granted. The shareholders of the company approved the plan at the company's annual meeting on September 14, 2023.
The stock options were issued in connection with the reporting person's Board of Director services to the Company.
The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date.
This amendment is being filed solely to correct the number of shares of common stock underlying the reported option issued on September 21, 2023, and the total number of derivative securities owned following the reported transaction.
/s/ Christopher Downs, Attorney-in-fact
2023-10-12